Isofol Medical
0.67 SEK
+2.92 %
Less than 1K followers
ISOFOL
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+2.92 %
-5.77 %
-8.23 %
-8.23 %
-16.37 %
-57.75 %
+24.40 %
-95.06 %
-95.04 %
Isofol Medical is a research-based biotechnology company working to improve the prognosis of patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment that is used globally for several forms of solid tumors. Isofol is conducting clinical development of arfolitixorin in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is great.
Read moreMarket cap
214.41M SEK
Turnover
197.03K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
19/5
2026
General meeting '26
19/5
2026
Interim report Q1'26
25/8
2026
Interim report Q2'26
All
Webcasts
Press releases
3rd party
ShowingAll content types
Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue
Finansinspektionen: Flaggningsmeddelande i Isofol Medical AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools